Literature DB >> 4704893

Epidermolysis bullosa dystrophica treated with vitamin E and oral corticosteroids.

W P Unger, J R Nethercott.   

Abstract

A 12-year-old boy with histologically proved epidermolysis bullosa dystrophica was treated daily with 10,000 IU of DL-alphatocopheryl acetate and prednisone 120 mg. Comparison of a control study period of seven weeks with the period during which vitamin E was given revealed no significant improvement. The same negative results were noted with the use of prednisone although the levels believed necessary to produce improvement were never attained owing to supervening infection.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4704893      PMCID: PMC1941377     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  8 in total

1.  TREATMENT OF EPIDERMOLYSIS BULLOSA DYSTROPHICA BY ALPHA TOCOPHEROL.

Authors:  H D WILSON
Journal:  Can Med Assoc J       Date:  1964-06-06       Impact factor: 8.262

2.  Studies on the pathogenesis of epidermolysis bullosa.

Authors:  R W PEARSON
Journal:  J Invest Dermatol       Date:  1962-12       Impact factor: 8.551

3.  Epidermolysis bullosa dystrophica with severe deformity of hands and pharyngeal stenosis, relieved by cortisone.

Authors:  E J MOYNAHAN
Journal:  Proc R Soc Med       Date:  1961-08

4.  Human skin collagenase: relationship to the pathogenesis of epidermolysis bullosa dystrophica.

Authors:  A Z Eisen
Journal:  J Invest Dermatol       Date:  1969-05       Impact factor: 8.551

5.  Bioavailability.

Authors:  R O Davies; D P Zarowny; H R Robin; J Ruedy
Journal:  Can Med Assoc J       Date:  1972-08-05       Impact factor: 8.262

6.  Vitamin E therapy in dystrophic epidermolysis bullosa.

Authors:  V N Sehgal; R K Sanyal
Journal:  Arch Dermatol       Date:  1972-03

7.  The management of epidermolysis bullosa in children. Effective topical steroid treatment.

Authors:  G L Severin; E M Farber
Journal:  Arch Dermatol       Date:  1967-03

8.  Comparative bioavailability of three brands of ampicillin.

Authors:  C MacLeod; H Rabin; J Ruedy; M Caron; D Zarowny; R O Davies
Journal:  Can Med Assoc J       Date:  1972-08-05       Impact factor: 8.262

  8 in total
  1 in total

Review 1.  Why don't we use vitamin E in dermatology?

Authors:  K Pehr; R R Forsey
Journal:  CMAJ       Date:  1993-11-01       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.